EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

March 16, 2020

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 41 min

Earnings Call Speaker Segments

Operator

operator
#1

Good afternoon. I'm the conference operator for Chorus. Welcome, and thank you for being with us on EL.En's call covering financial results for Full Year 2019. <<operator_script>> Right now, I'll hand the conference over to Mr. Nicola Fiore. Sir, please go ahead.

Executive

executive
#2

Thank you, and good afternoon, everyone — we appreciate you joining us. Joining me today are Andrea Cangioli, Managing Director of EL.En, and Enrico Romagnoli, EL.En's Chief Financial Officer and Investor Relations. Before we get started, I'd like to remind you that management's recent comments on this conference call regarding future expectations, plans and prospects constitute forward-looking statements. Some of the statements made on this call — including those that touch on the company's beliefs, plans, objectives, estimates or expectations about possible future results or events — are forward-looking statements. Such statements carry known or unknown risks, among them general economic and business conditions and conditions in the industry where the company operates, which could be affected if our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from what is expected — whether expressed or implied in those forward-looking statements. The company assumes no obligation regarding the content, nor to update the forward-looking statements to reflect events or circumstances arising after the date hereof. At this point, I'll hand the call over to Andrea Cangioli. Andrea, please go ahead.

Andrea Cangioli

executive
#3

Thanks, Nicola. Many thanks, and thanks to all of you for being on this call about the financial report for the entire 2019 year, which we issued on Friday. As always, Enrico Romagnoli will walk you through the specifics of our financials; I'll offer a very short set of highlights on the year and then devote more time to where our business and activities stand right now. 2019 truly was an outstanding year. Even with the significant fees and accounting write-offs required under International Accounting Standard 15, our consolidated revenues got past the EUR 400 million threshold. With metrics improving across every measure, our EBIT rose 27% to EUR 38.2 million and lifted its margin on revenue. Even with the EUR 4.6 million adjustment required under Accounting Standard 16, even with EUR 8.6 million in dividends and EUR 23 million of investment in fixed assets, and even with revenue growth of 15% and more that naturally required working capital funding, in spite of all that, the net financial position essentially remained at the level where it stood at the start of the year. The overall result was excellent, and almost every one of our businesses added to the growth in revenues and profit.

Andrea Cangioli

executive
#4

Just 2 segments had a tough time this year. Monna Lisa Touch in the United States came in at 0 for the year. Worldwide we didn't do too badly, but if you take away the drag from U.S. sales, keeping a positive sales trend for this product globally will be hard. The other struggling area was cutting system sales in China, which posted a slight slowdown against a pretty strong headwind from the tariff war and its knock-on effects on how the overall Chinese economy performed. Most of our competitors booked a double-digit reduction in sales, but our competitive position let us limit the decline in China and delivered a worldwide 70% increase in laser cutting system sales, thanks to the excellent pickup in sales in Europe and in Italy during the second half of the year. Those were the 2 slots, the only slots, so to speak, of 2019. Every other segment ranged from good to very good to extraordinary. Urology and hair removal led the way in terms of sales growth. Quanta System in terms of profitability jointly to utilize it, which, I recall, specializes in laser marking systems with a market of identification.

Andrea Cangioli

executive
#5

Our new Onda Coolwaves system did really well in the body shaping market. When it came to hair removal, Asclepion's MeDioStar Monolith was the top seller, and we have several new products lined up and ready to launch in 2020. We finished most of the construction work aimed at strengthening our logistics and our production capacity. The initial EUR 30 million budget turned out not to be enough because of the decision on the run of 3 projects. The first is the new plant, Lin Yi, which is our third plant in China; the second is a plant larger than expected that Cutlite Penta needs here in Prato, roughly 10 kilometers from where I am speaking right now in Calenzano, where Penta moved to December ; and the third is the refurbishment of the plant that Cutlite Penta itself left vacant by midyear, a surface that the new 4.0 plant for our mid-power CO2 RF laser sources is going to occupy. Now, Enrico, please go ahead with the details of 2019.

Enrico Romagnoli

executive
#6

Thank you, Andrea, and good morning everyone. As Andrea already noted, 2019 delivered strong growth in sales volume and profitability. Revenue came in above EUR 400 million, a 16% increase over the prior year. The fourth quarter was excellent as well, with turnover of EUR 117 million and an operating result of EUR 11.7 million, equal to a 10% impact on sales. It's also worth remembering that during the period, EUR 1.5 million of sales to a leasing company with our purchasing obligation were accounted for in compliance with IFRS 15. So those sales were recognized as multiyear rentals even though the price had already been fully collected. The negative impact on operating income was EUR 0.6 million relative to our traditional accounting. The lower revenues and margin for the year will be recovered linearly over the multiyear period during which the operating leasing contracts remain effective. Gross margin was EUR 156 million, up 13.5% from EUR 137 million last year. The slight decline in sales margin, from 39.7% to 38.9%, stems from a modest margin decrease in both sectors, Medical and Industrial, and is also affected by a small reduction in grants received.

Enrico Romagnoli

executive
#7

Operating costs came in at EUR 43.6 million, an increase of 1.8%, and staff costs reached EUR 66.1 million, rising 12% from EUR 59 million a year earlier. At December, the group employed almost 1,500 people, which is 130 more than at the start of the year, and China accounted for most of that growth. EBITDA totaled EUR 46.3 million, 30% higher than the EUR 35.7 million posted last year, representing 11.6% of sales. Amortization and other accruals amounted to EUR 8.1 million, up 44% from EUR 5.6 million last year, driven by capital expenditure made during the year as well as higher bad debt accrual and warranty accrual on products sold. It is also worth noting that IFRS 16 took effect on January 1, and EUR 1.6 million was reclassified from operating cost into depreciation. Over 12 months, fixed cost — meaning operating cost plus staff cost and depreciation — saw its impact on sales fall from 31.1% to 29.4%, delivering a positive leverage effect on the operating result. Accordingly, EBIT was EUR 38.2 million, up 27.4% from EUR 30 million last year, while its impact on sales improved to 9.5% from 8.7% a year ago.

Enrico Romagnoli

executive
#8

Pretax result came in at EUR 38.6 million, while net income reached EUR 20 million, a rise of 55%, with earnings per share of EUR 1.33 versus EUR 0.8 in the prior year. The group's net financial position recorded a positive balance of EUR 61.4 million, which is EUR 1 million below year-end, yet cash generation stayed strong in the fourth quarter at EUR 10 million, and the ratio of net working capital to sales improved from 29.5% to 27.6%. The year's principal cash outflows were dividends of EUR 8.7 million and capital expenditure of EUR 23 million, of which EUR 14 million went to new buildings and factories. It should also be noted that IFRS 16 affects the net financial position as well, by EUR 4.8 million. Excluding that, the net financial position would have exceeded EUR 66 million and been higher than the previous year. In the fourth quarter, Quanta System put EUR 2.5 million into an insurance policy, adding to the EUR 12 million EL.En. had already invested over the past year. Investments of this kind, being long-term by nature, are classified among non-current financial assets and therefore are not counted in the net financial position.

Enrico Romagnoli

executive
#9

Within Medical, after-sales service accounted for over 60% of group turnover in 2019 and posted the strongest growth, with revenue rising roughly 36% and reaching about 19% of Medical sector sales. Every revenue type in this category contributed to that notable outcome — creams and accessories in beauty, full-risk contracts for technical assistance, and ordinary service on the installed base — but the biggest contributors were upgrades on the IPL hair removal system and sales of single-use and multi-use optical fibers for urological applications. Note that upgrades already booked in the prior year represent a revenue type that cannot be repeated in full next year. In Medical, urology sales within the surgery segment stand out; second is volume solely for the application segment that has historically mattered most to the group, hair removal. Growth for laser systems exceeds 19%, but when laser system turnover is combined with that of optical fibers recorded in the service segment, which contains consumable goods, this business overall came close to EUR 50 million in 2019, up 46% versus the same period last year.

Enrico Romagnoli

executive
#10

Aesthetic posted a gain of roughly 22% and stayed the group’s most relevant segment, thanks to continued expansion in the hair removal and tattoo removal application area. A meaningful share of turnover comes from Onda Coolwaves by Deka for body contouring — EUR 11 million in sales across the full year — and from B-star, distributed in Italy by Esthelogue for the professional aesthetics sector. Taken together, body became one of the most relevant segments in 2019, trailing only hair removal and comparable in size to tattoo removal. The Industrial sector, by contrast, met with less favorable conditions in 2019 than in recent years. Even so, annual growth in that sector is 4.4% for the system and 7% overall, service included, and service posted a jump of more than 40%. The laser sector grew 3.6% — not a bad result in absolute terms or against general manufacturing trends, but well below recent growth rates. In our most important market, Wuhan in China, after a very rapid start in the first month of the year, plus 15% in H1, H2 showed a revenue decrease of 17%. So for the year in China we had an overall reduction of 2%.

Enrico Romagnoli

executive
#11

The marketing division continues to perform very well, particularly within the identification market, where our subsidiary Lasit — based in Torre Annunziata, Naples — operates. Over the 12 months, we saw growth exceeding 13%. Results for laser sources fell 9%, affected by the market downturn. In the Industrial sector as well, the strongest expansion came from after-sales services and consumable sales, posting a rise of more than 44%, helped by the consistency of the installed base. Turning to revenue distribution across geographical areas, the Medical sector's biggest growth occurred in ex-European countries, with Europe next, whereas the Italian market held steady. During the period, our competitive position and profitability recovered in the Japanese aesthetic market following a very poor year in 2018. That was helped by sales to a large chain of beauty centers of small aesthetic systems suited to home use, and by the upgrade on the IPL system. In addition, Quanta System delivered excellent results in urological systems, sold in particular to American OEMs. In the Industrial sector, we saw a very good performance from Cutlite Penta for cutting and from Lasit for marking in Italy and Europe, with a slowdown in China and Brazil. Andrea, please go ahead.

Andrea Cangioli

executive
#12

All right. Thank you, Enrico. So you've heard every detail about our excellent 2019. When 2020 began, it carried all of that positive momentum from 2019, plus the rebound in order bookings in China that had gotten underway with the month of December. Then all at once the world shifted. China first. The wide spread of COVID-19 pushed the Chinese authority to lock down the city of Wuhan along with several other provinces of China, catching them at the pre-festival vacation. What at first seemed a minor issue proved to be a major epidemic disease, and it brought most business activities in China to a standstill for more than a month. Our 3 factories were forced to shut down, and only in early March could Lin Yi and Wenzhou begin operating again, while the Wuhan factory remains closed and likely will stay that way for at least this current week. Operations in Lin Yi and Wenzhou are not at full capacity, since a number of our employees come from Wuhan, where they were on their break when the real virus exploded and where their feet stuck. Reports on the present market mood are not bad. We are beginning to sell again. But of course it is very hard to predict how long the market will take to get back to its standard levels, and that covers the Chinese part.

Andrea Cangioli

executive
#13

Beyond our borders, life appears able to carry on free of the virus, yet what has happened lately and the numbers coming out of Italy initially, then a number of European nations and ultimately U.S. counties and at last the U.S. itself, indicate that the coronavirus would sweep across the globe. As you may be aware, the whole of Italy is living today under semi-quarantine conditions. Every shop, pharmacy, food store and supermarket is shut. Hotels and restaurants are shut. Factories may operate, but in a highly complicated environment, particularly in Northern Italy, where thus far the virus has struck with greater force, with hundreds of casualties. Right now, our Quanta System plant in Samarate — one of the so-called red areas, heavily affected by the epidemic — has been closed for 2 weeks. A similar decision could be made in Florence and in Prato, though it has not been made yet, and among the other clients located in Italy. No European employee of ours has been reported as positive for the virus. The safety and health of our employees and partners is our foremost responsibility and concern. At this particular moment, we must comply with the regulations and cannot let our very valuable employees feel uncomfortable or at risk.

Andrea Cangioli

executive
#14

Meanwhile, travel has been prohibited, and international sales across every one of our businesses — Medical, Surgical and Industrial — have either been canceled or postponed. So right now, we find ourselves in a sharply unfavorable climate. Output has stopped in China and at one plant in Italy. We had what I'd call a rich, indeed record, backlog, but it's difficult at this point to say when the market will return to normal and how long it will take for confidence to be restored — the confidence that demand for capital goods like those we make and sell requires. That's why we chose to withhold guidance. We don't want to be overly optimistic by modeling a brief shutdown period or 2 facilities seeing a very lengthy one. Certainly, our numbers will take a hit, but I can't reasonably forecast the size of it. Before I hand the session over to your questions, I'd like to mention that we have a number of good news items and a great many positive things prepared for 2020. For example, we have just obtained FDA clearance for high-power hair removal laser systems to be sold in the United States, which is among the areas where the strongest growth was expected for 2020.

Andrea Cangioli

executive
#15

And on top of that, the positive news — the broad positive news is that the momentum we showed during 2019 and at the start of 2020, our ability to hold up and our determination to stand firm in the current situation, are really strong, along with a readiness to respond and to give our very best effort and — pardon me, as soon as this stretch that will likely be affecting, most of our award has passed, we will return with every one of our resources prepared to get moving once more. So thanks for listening, and please proceed with your questions.

Operator

operator
#16

<<operator_script>> Our first question comes from Andrea Bonfa at Banca Akros.

Andrea Bonfà

analyst
#17

First off, I’d like to ask about Q4’s operational leverage. It isn’t especially relevant right now, but just out of curiosity — your mix looked quite good, with strong growth in Medical and Surgical. Still, operational leverage didn’t really stand out, especially when set against the 9-month performance. If you could expand on that, please. Second, and of course mostly tied to the current economic situation, is the coronavirus impact. In the likely scenario, or a global recession in H2 2020, the path of your fixed costs and, say, variable costs — I mean all those costs below gross margin — how would you manage them in the hypothetical case of a sales decline? Are those still set to rise? Or can you manage those aggregate costs? And if I may, on the third — sorry, point, my curiosity is this: if we conclude that a recession is coming, you might need to help your clients by extending payments. So would you use your cash to support working capital? Or would you consider starting a buyback of your shares?

Andrea Cangioli

executive
#18

Thanks, Andrea. Three questions. First, leverage in Q4. The reason you noted what you did for Q4 is that sales in China were very, very low relative to cost. We have a structure that begins with a certain level of cost. We were expecting a certain level of revenue. Revenue in China, as a result of the low older collection during December, was low. We did a little bit better in December. But during October and November, our sales level was very low. Then, as I said earlier, we had good order booking in December and the beginning of January before everything stopped. And the second question concerns fixed costs. Of course, large portions of certain fixed costs, for instance at this moment, are gone. All the international sales are not going to take place. So we are not going to pay the international fares. We are not going to pay any international traveling. We are not going to pay all the expenses, all the traveling, and also the training that is very relevant with our customer, and it's cost -- it's part of the fixed cost. So we will be able to cut these kinds of costs.

Andrea Cangioli

executive
#19

Employee costs are easily the biggest piece. So, for example, in Italy, where we're slowing things down, we have people going home and working from there. From home, they're probably working a bit less than they do here. Production will likely have to — will need to be slowed, since we probably won't be allowed to ship, at least over the very next weeks, because of — I mean, we could see some volume reduction. In that case, I mean, we'll first — our employees will get the benefit of their time off. And then we'll see whether the period ends up being extremely long, whether we'd need to invoke the standard state support for these occasions. Ironically, we're far from that situation, because our books — our order book is extremely interesting. As I told you, we had record order books running into the period. But we need now to see how everything develops worldwide, because we might run into difficulties shipping all the groups we have on the order books to our customer, given the worldwide spread of the virus. So, I mean, in a nutshell, we have — we can have some handle on the fixed cost, trying to reduce them in case of revenue limitation like what we'll encounter over the very next weeks.

Andrea Cangioli

executive
#20

On your third question, you're correct. The share price has fallen to a really low level, and that makes it appealing as an investment, including for the company itself. As I see it, we've already set aside a solid amount of cash for dividend payments, and we kept those unchanged, even though we're aware that a very, very tough year lies ahead. We'll find out what sort of financial consequences the virus brings. Should there be a credit crunch, the way it happened in 2009, we would likely be compelled to draw on part of our cash to prop up our most valuable customer. But at this stage it's too early — what I mean is, too early to see and to give you any forecast about what we'll manage to do. Honestly, at this moment — I mean, as of today, we're still shipping, and we don't foresee issues with our customers, and I'm referring to foreign customers. That could shift tomorrow, or the day after tomorrow. One thing certain right now: we aren't shipping anything at all to customers in Italy, since our Italian customers in the medical system — in the medical market — are unable to operate.

Operator

operator
#21

François Robillard with Intermonte has the next question.

François Robillard

analyst
#22

First, just to clarify — Enrico mentioned the FDA clearance for a product in the U.S., but the name of that product wasn't mentioned. If you could just come back on that. Then another thing is on the recent FDA clearance on the Coolwaves. What are your expectations, although I guess it might be difficult to give at that point. Then if you can give us an update on the works done at all the plant enhancements that you announced until late last year — are they all over and ready to operate? And finally, your recent investment in minorities, about that? Is it too early to think about some impairments on those assets?

Andrea Cangioli

executive
#23

Alright, three questions. Onda got a clearance in the United States, but that clearance isn't for Onda as such — it's for products similar to Onda in terms of their specifications and, most importantly, their intended use, which <<inaudible>> differs somewhat from Onda's. That system, in any case, will be sold in the United States by a new distributor of ours called <<inaudible>>, which has a strong distribution network across the United States. The other product, for hair removal, will be sold through an OEM partnership, and the name is <<inaudible>>. The other question was then about the minorities in China. Well, the transaction happened in the first half of 2019 with the purchase by Wenzhou of Wuhan, and the second part in January 2020 with the purchase and payment by Ot-las of roughly 30% more of Penta Wenzhou. I think it's really too early to begin talking about impairment. Of course, the results in 2020, particularly in the first half, will be far from what we would have expected on January 15 when we paid — we sent a wire to make the payment. But we are extremely confident that the market will come back and that we'll be able to complete our, let's say, business case in developing our business capacity in China and seeing further growth in this market.

Andrea Cangioli

executive
#24

Naturally, we did hand over a substantial portion for that stake — this 30% interest in our business. Still, at this point, I think we can, I think, continue to justify — still justify — the worth of the deal. Sorry, François, what was your third question again? I can't recall it.

François Robillard

analyst
#25

Sorry. Just regarding the construction and upgrade of the plants, could you give us an update — have they all been completed?

Andrea Cangioli

executive
#26

Yes, yes, the plants—we haven't finished all of them, because some work will carry over into 2020, and that work is going to be slowed down as well. The biggest piece of that slowed work is the Chinese completion of the Wenzhou plant. So we wrapped up the new plant in 2019. The grand opening took place in December. But the second Wenzhou facility isn't fully done yet, and it will proceed slowly, given the current state of the Chinese economy. We have to finish the new building here in Florence for the industrial laser source—for manufacturing the medium-powered CO2 RF-excited laser sources. And we still need to fully complete the move of Lasit in Torre Annunziata into the new building, with some expenses involved, but we're talking about "minor, minor" expenses. We had been planning an expansion, which was something entirely unplanned, but it was needed because of how fast the European and Italian business of Cutlite Penta has been growing. We plan to expand our production capacity further in Prato, since at the pace we saw in November and December, it was no longer sufficient.

Andrea Cangioli

executive
#27

Our growth has been genuinely strong, in a very, very powerful manner. But naturally, that investment is now paused.

Operator

operator
#28

<<operator_script>> We now have a follow-up question from Andrea Bonfa at Banca Akros.

Andrea Bonfà

analyst
#29

Let me just offer something from our end, if that's at all possible. The truth is, forecasting the first quarter — and China in particular — puts us in genuinely uncharted territory. So we were hoping you might give us guidance on what you expect for sales in China within the laser — the industrial laser division — because in our preliminary assumptions we've put down minus 50%, though perhaps that's too small. Are we headed toward minus 80, minus 70, minus 30s? Some sense of what we should be anticipating, at least for China in the first quarter, would help. After that we can perhaps adopt some recovery scenario for the subsequent quarters. And — Andrea, if I may — could you give us some color: outside of Wuhan, is the economic situation, let's say, really improving gradually? And with economic activity, let's say, coming back to a normal level, what inputs from your side could you share with us?

Andrea Cangioli

executive
#30

To pick up with the final question: the data we're getting is reasonably encouraging, and it suggests the economy is getting back to healthy levels. Plus, we know our salespeople — the ones who are able to get out, since a lot of them were based in Wuhan and couldn't move — have begun taking new orders. So in the first 15 days of March we started booking orders, which was a very positive sign, because from that angle we've seen decent activity. As for the turnover we expect in Q1, we didn't provide guidance, and I'm not going to give you a number now, but the arithmetic is pretty straightforward. We worked 15 days before the spring break, and after those 15 days we restarted at very low rates — let's say 50%, with under 50% of our capabilities, on a market that was, and still is, extremely, extremely, extremely slow. So we're not expecting an impressive figure — not a good sales number — for our Chinese activities in the first quarter of 2020.

Operator

operator
#31

<<operator_script>> Mr. Cangioli, at this point we have no further questions.

Andrea Cangioli

executive
#32

Alright, thanks for joining us at this point. And we — I’m hoping we’ll have another meeting with you in a few weeks, when we’ll present the first quarter financials. That ought to happen roughly — yes, 2 months from now — roughly 2 months from now. And I hope by then to be in a position to give you a far clearer picture of how our business is going to develop, and above all I hope that by that time, most of the hits we took and are taking because of the coronavirus situation will be behind us. Thanks for being with us.

Operator

operator
#33

Ladies and gentlemen, thanks for being with us. That brings the conference to a close. You're free to hang up your phones now. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.